This aligns with a study by Krijgsman et al. that suggests that human malignant cells can induce de novo expression and presentation of HLA‐G molecules, which could be potentially important for the treatment of tumour patients with monalizumab [41]. This evidence concerns the gene HLA-G and neoplasm.